Repository logo
 

SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies.

Simple item page
cam.depositDate2022-02-25
cam.issuedOnline2021-03-11
cam.orpheus.success2022-03-07 - Embargo set during processing via Fast-track
dc.contributor.authorCollier, Dami A
dc.contributor.authorDe Marco, Anna
dc.contributor.authorFerreira, Isabella ATM
dc.contributor.authorMeng, Bo
dc.contributor.authorDatir, Rawlings
dc.contributor.authorWalls, Alexandra C
dc.contributor.authorKemp S, Steven A
dc.contributor.authorBassi, Jessica
dc.contributor.authorPinto, Dora
dc.contributor.authorFregni, Chiara Silacci
dc.contributor.authorBianchi, Siro
dc.contributor.authorTortorici, M Alejandra
dc.contributor.authorBowen, John
dc.contributor.authorCulap, Katja
dc.contributor.authorJaconi, Stefano
dc.contributor.authorCameroni, Elisabetta
dc.contributor.authorSnell, Gyorgy
dc.contributor.authorPizzuto, Matteo S
dc.contributor.authorPellanda, Alessandra Franzetti
dc.contributor.authorGarzoni, Christian
dc.contributor.authorRiva, Agostino
dc.contributor.authorCITIID-NIHR BioResource COVID-19 Collaboration
dc.contributor.authorElmer, Anne
dc.contributor.authorKingston, Nathalie
dc.contributor.authorGraves, Barbara
dc.contributor.authorMcCoy, Laura E
dc.contributor.authorSmith, Kenneth Gc
dc.contributor.authorBradley, John R
dc.contributor.authorTemperton, Nigel
dc.contributor.authorCeron-Gutierrez L, Lourdes
dc.contributor.authorBarcenas-Morales, Gabriela
dc.contributor.authorCOVID-19 Genomics UK (COG-UK) consortium
dc.contributor.authorHarvey, William
dc.contributor.authorVirgin, Herbert W
dc.contributor.authorLanzavecchia, Antonio
dc.contributor.authorPiccoli, Luca
dc.contributor.authorDoffinger, Rainer
dc.contributor.authorWills, Mark
dc.contributor.authorVeesler, David
dc.contributor.authorCorti, Davide
dc.contributor.authorGupta, Ravindra K
dc.contributor.orcidDatir, Rawlings [0000-0003-0521-2144]
dc.contributor.orcidSmith, Kenneth [0000-0003-3829-4326]
dc.contributor.orcidBradley, John [0000-0002-7774-8805]
dc.contributor.orcidWills, Mark [0000-0001-8548-5729]
dc.date.accessioned2022-03-08T00:30:06Z
dc.date.available2022-03-08T00:30:06Z
dc.date.issued2021-02-15
dc.date.updated2022-02-25T10:08:42Z
dc.description.abstractSevere Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) transmission is uncontrolled in many parts of the world, compounded in some areas by higher transmission potential of the B1.1.7 variant now seen in 50 countries. It is unclear whether responses to SARS-CoV-2 vaccines based on the prototypic strain will be impacted by mutations found in B.1.1.7. Here we assessed immune responses following vaccination with mRNA-based vaccine BNT162b2. We measured neutralising antibody responses following a single immunization using pseudoviruses expressing the wild-type Spike protein or the 8 amino acid mutations found in the B.1.1.7 spike protein. The vaccine sera exhibited a broad range of neutralising titres against the wild-type pseudoviruses that were modestly reduced against B.1.1.7 variant. This reduction was also evident in sera from some convalescent patients. Decreased B.1.1.7 neutralisation was also observed with monoclonal antibodies targeting the N-terminal domain (9 out of 10), the Receptor Binding Motif (RBM) (5 out of 31), but not in neutralising mAbs binding outside the RBM. Introduction of the E484K mutation in a B.1.1.7 background to reflect newly emerging viruses in the UK led to a more substantial loss of neutralising activity by vaccine-elicited antibodies and mAbs (19 out of 31) over that conferred by the B.1.1.7 mutations alone. E484K emergence on a B.1.1.7 background represents a threat to the vaccine BNT162b.
dc.identifier.doi10.17863/CAM.82166
dc.identifier.issn0028-0836
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/334736
dc.language.isoeng
dc.publisherNature Research
dc.publisher.departmentDepartment of Medicine
dc.publisher.departmentoffice of The School of Clinical Medicine
dc.rightsAll Rights Reserved
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserved
dc.subjectThe CITIID-NIHR BioResource COVID-19 Collaboration
dc.subjectThe COVID-19 Genomics UK (COG-UK) consortium
dc.titleSARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies.
dc.typeArticle
dcterms.dateAccepted2021-03-01
prism.publicationDate2021
prism.publicationNameNature
pubs.funder-project-idCambridge University Hospitals NHS Foundation Trust (CUH) (BRC 2017-22)
pubs.licence-display-nameApollo Repository Deposit Licence Agreement
pubs.licence-identifierapollo-deposit-licence-2-1
rioxxterms.typeJournal Article/Review
rioxxterms.versionAM
rioxxterms.versionofrecord10.1038/s41586-021-03412-7

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
393570_2_accepted_merged_1613493811.pdf
Size:
6.25 MB
Format:
Adobe Portable Document Format
Description:
Accepted version
Licence
http://www.rioxx.net/licenses/all-rights-reserved
Download

Collections

Cambridge University Research Outputs